# PATINA

Source: https://onco.cc/trials/patina/  
OnCo record `patina` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PATINA showed that adding the CDK4/6 inhibitor palbociclib to maintenance antibody and hormone treatment kept breast cancers that are both hormone receptor- and HER2-positive under control for markedly longer.

## Summary

About half of HER2-positive breast cancers also express hormone receptors, and the two signalling routes cross-talk. PATINA randomised 518 patients with hormone receptor-positive, HER2-positive metastatic breast cancer who had completed four to eight cycles of induction chemotherapy with trastuzumab and pertuzumab without progression to maintenance anti-HER2 therapy plus endocrine therapy with or without palbociclib. The primary endpoint was investigator-assessed progression-free survival.

Palbociclib lengthened progression-free survival substantially with manageable toxicity, mainly neutropenia. The result, reported in December 2024, established CDK4/6 inhibition as part of maintenance for this double-positive group.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Tags: subtype-trials
- Registry id: NCT02947685
- Phase: 3
- Setting: Hormone receptor-positive, HER2-positive metastatic breast cancer after induction chemotherapy with anti-HER2 therapy: maintenance anti-HER2 therapy and endocrine therapy with or without palbociclib
- Sponsor: Alliance Foundation Trials with Pfizer
- Enrolled: 518
- Result: Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival.

## Sources

- ClinicalTrials.gov NCT02947685: https://clinicaltrials.gov/study/NCT02947685

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/patina.json